Gender, race, and HIV therapy: Insights from the GRACE study

©2013 Mary Ann Liebert, Inc., publishers

Enrollment of women in clinical trials of new anti-HIV drugs is extremely low, representing only about 15% of all treatment-experienced patients. For women of color it is even lower. Why women, and especially women of color, are so poorly represented in HIV drug trials is the focus of an important article in AIDS Patient Care and STDs, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

HIV-infected individuals that participated in the GRACE study, conducted from October 2006-December 2008, received based on a darunavir/ritonavir . More than half of the trial participants completed a survey between 2010-2011 to evaluate their experiences, opinions, and outcomes. The survey showed that 76% of the respondents felt that the GRACE trial made them feel differently about their health/HIV care, 82% became more focused on their health, and 87% continued treatment after GRACE.

Access to treatment was reported as the most positive factor in patient enrollment, according to authors Kathleen Squires and colleagues from Jefferson Medical College of Thomas Jefferson University (Philadelphia, PA), University of Cincinnati College of Medicine (OH), The Well Project, Inc. (Nellysford, VA), University of California, Los Angeles, Janssen Research & Development, and Janssen Services (Titusville, NJ).

Factors associated with difficulties in adherence to HIV medications, a critical part of maintaining healthy lives, included being the primary caregiver for children, unemployment, and transportation difficulties. These findings were reported in the article "Insights on GRACE (Gender, Race, and Clinical Experience) from the Patient's Perspective: GRACE Participant Survey."

"Identification of patients at high risk for suboptimal clinical trial outcomes through surveys such as these should help improve HIV medication compliance and retention," says Editor-in-Chief Jeffrey Laurence, MD, Director of the Laboratory for AIDS Virus Research at Weill Medical College of Cornell University, New York, NY.

More information: The article is available free on the AIDS Patient Care and STDs website at http://www.liebertpub.com/apc.

add to favorites email to friend print save as pdf

Related Stories

Are there gender differences in anti-HIV drug efficacy?

Aug 09, 2012

Women comprise nearly half of the HIV-infected population worldwide, but these 15.5 million women tend to be under-represented in clinical trials of anti-HIV drug therapies. The U.S. Food and Drug Administration ...

Integrating mental health care into HIV care

May 21, 2013

The integration of mental health interventions into HIV prevention and treatment platforms can reduce the opportunity costs of care and improve treatment outcomes, argues a new Policy Forum article published in this week's ...

Patient satisfaction leads to better HIV care

Jan 30, 2013

In a study of patients at two HIV clinics in the Houston area, researchers at Baylor College of Medicine and the Michael E. DeBakey Veterans Affairs Medical Center found that those who were satisfied with the care they received ...

Recommended for you

Model explains why HIV prevention dosing differs by sex

28 minutes ago

A mathematical model developed by NIH grantees predicts that women must take the antiretroviral medication Truvada daily to prevent HIV infection via vaginal sex, whereas just two doses per week can protect men from HIV infection ...

Tourism as a driver of illicit drug use, HIV risk in the DR

23 hours ago

The Caribbean has the second highest global human immunodeficiency virus (HIV) prevalence in the world outside of Sub-Saharan Africa, with HIV/AIDS as leading cause of death among people aged 20–59 years within the region. ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.